Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q2 FY21 Earnings Presentation
15 slides from Alembic Pharmaceuticals's earnings presentation, September 2020
Slide 1: Alembic Pharmaceuticals Limited Investor presentation – September 2020
Alembic Pharmaceuticals Limited Investor presentation – September 2020 BSE & NSE: APLLTD
Slide 2: Milestones
Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed 2012 Formed a JV, Rhizen, for NCE research Launched fir
Slide 3: Financial Highlights
Financial Highlights INR Bn Particulars Q2 FY21 Q2 FY20 Growth H1 FY21 H1 FY20 Growth YTD FY20 Net Sales 14.57 12.41 17% 27.98 21.90 28% 46.06 EBIDTA Pre R&D 6.28 5.05 24% 11.77 8.36 41% 18.15 Margin % 43% 41% 42% 38% 39% R&D 1.85 1.74 6% 3.27 3.14 4% 6.45 R&D % 13% 14% 12% 14% 14% EBIDTA Post R&D 4
Slide 4: Business snapshot – Q2FY21
Business snapshot – Q2FY21 Formulations Generics Branded API Total US Ex-US India Revenue Q2FY21 (INR Bn) 5.82 1.97 4.15 2.63 14.57 API Vet 18% 18% 40% 4% Generics Q2FY21 Revenue 53% Acute Contribution 10% Branded 28% 14% Speciality 15% Growth Q2FY21 8% 84% 6% 29% 17% over Q2FY20 Growth Q2FY21 -2% 1
Slide 5: Business snapshot – H1FY21
Business snapshot – H1FY21 Formulations Generics Branded API Total US Ex-US India Revenue H1FY21 (INR Bn) 11.77 3.73 7.21 5.28 27.98 API Vet 19% 19% 3% H1FY21 Revenue Generics 42% 55% Contribution Acute 8% Branded Speciality 14% 26% 13% Growth H1FY21 33% 73% 1% 40% 28% over H1FY20 • Well-established
Slide 6: US Generic
US Generic INR Bn Revenue – Q2 FY21 INR Bn Revenue – Last 4 Years CAGR - 29% 19.76 5.82 5.39 12.88 9.19 9.20 Q2FY20 Q2FY21 FY17 FY18 FY19 FY20 Approved ANDAs Derma Injectable 1 12 ➢ Well-established US front end having strong customer base Ophthalmic 12 ➢ Expanded our capabilities to deliver a diver
Slide 7: Ex-US Generics
Ex-US Generics Revenue : Q2 FY21 INR Bn Revenue – Last 4 Years INR Bn CAGR - 16% 1.97 1.07 4.94 4.97 Q2FY20 Q2FY21 3.20 ➢ Ex-US driven by partnership 2.86 ➢ Presence in following markets - Europe, Canada, Australia, Brazil and South Africa ➢ The business will focus on new launches across key markets
Slide 8: API
API Revenue : Q2 FY21 INR Bn Revenue – Last 4 Years INR Bn 2.63 CAGR - 3% 2.04 7.71 7.08 6.40 6.51 Q2FY20 Q2FY21 ➢ Sales across geographies as preferred supplier ➢ Investing in plants to create additional capacities ➢ FDA Compliant plants ➢ State of the art R&D center and Process development lab ➢ 1
Slide 9: R&D: Significant investments in building capabilities
R&D Significant 10.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 37* 8.0 Filing 13.7% 14.0% 13.1% 12.7% 29 30 Approval 6.0 25 10.1% R&D Spend 20 19 18* * 11 Filings & 4.0 7 Approvals 6.5 R&D % of 10 were 5.0 sales 2.0 4.3 4.1 8 contributed by 3.2 5 acquisition
Slide 10: State of the art facilities and infrastructure
State of the art facilities and infrastructure Audit/Filing Location Dosage Form status International Generics F1 – Panelav General Oral Solids Mar’20* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables H2FY21# F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Jan’2
Slide 11: Branded Business
Branded Business Revenue – Q2 FY21 INR Bn Revenue – Last 4 Years CAGR - 4% INR Bn 4.15 14.3 3.91 6% ↑ 13.8 0.40 0.52 12.5 12.7 Vet 1.40 1.43 Acute Speciality 2.11 2.20 Q2FY20 Q2FY21 FY17 FY18 FY19 FY20 Marketing organization Key achievements ➢ 5000 + Marketing team ➢ 3 Brands in top 300 ➢ 17 Marketi
Slide 12: Therapy-wise Performance Q2 FY21
Therapy-wise Performance Q2 FY21 Q2 FY21 Q2 FY20 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 15 2.1 14 16 12 2.1 4 1 Gynecology 1 2.7 4 -1
Slide 13: Therapy-wise Performance H1 FY21
Therapy-wise Performance H1 FY21 H1 FY21 H1 FY20 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 14 2.1 13 18 12 2.1 6 1 Gynecology -4 2.6 -6 -
Slide 14: Financials : Generating consistent returns
Financials : Generating consistent returns Revenue INR Bn EBIDTA Net Profit INR Bn 46.06 INR Bn 12.13 39.35 8.29 31.34 31.31 8.75 5.84 6.15 6.42 4.03 4.13 FY17 FY18 FY19 FY20 FY17 FY18 FY19 FY20 FY17 FY18 FY19 FY20 CAGR - 14% CAGR - 25% CAGR - 27% EBIDTA margin % Capex ROCE % INR Bn 32* 26 6.97 30*
Slide 15: Thank you
Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu
Alembic Pharmaceuticals — Q2 FY21 Earnings Presentation on 6ix